Patients | Case 1 | Case 2 | Case 3 | Case 4 | Case5 | Case 6 | Case 7 | Case 8 | Case9 |
---|---|---|---|---|---|---|---|---|---|
At diagnosis | |||||||||
Age | 1 m | 3 m | 1 m | 6 y11 m | 9 y1m | 2 y9m | 4y8m | 8 y11m | 8 y6 m |
Gender | M | M | F | F | F | M | M | M | M |
Gestational age(w + d) | 38 + 1 | 37 + 6 | 34 + 6 | 38 + 4 | 39 + 1 | 38 + 6 | 37 + 5 | 37 + 5 | 38 |
Birth weight (kg) | 2.7 | 2.7 | 1.4 | 3.5 | 3.5 | 3.3 | 2.6 | 3.15 | 2.5 |
Family history of diabetes | Father | Father/ Grandmother | Mother | Mother | Mother | Mother/ Grandfather | Father | Mother/ Grandmother | Father/ Grandfather |
BMI percentile | 50th | 25th | No data | 25th | 50th | 25th | 75th | 50th | 50th |
FPG (mmol/L) | 8.5 | 7.2 | 6.5 | 6.8 | 6.1 | 7.1 | 7.3 | 7.1 | 7.2 |
OGTT 2hPG (mmol/L) | No data | 8.0 | 9.6(at 3 m) | 7.8 | 7.6 | 7.6 | 8.4 | 8.2 | 8.8 |
2hPG increment (mmol/L) | No data | 0.8 | 3.1 | 1.0 | 1.5 | 0.5 | 1.1 | 1.1 | 1.6 |
HbA1c (%/mmol/mol) | 5.8/39.9 | 5.2/33.3 | 4.6/26.8(at 3 m) | 5.7/38.8 | 5.8/39.9 | 5.9/41.0 | 6.6/48.6 | 6.5/47.5 | 6.7/49.7 |
Fasting Ins (pmol/L) | 30.5 | 29.7 | 13.1 | 30.9 | 31.5 | 24.9 | 15.1 | 7.8 | 23.5 |
DKA | no | no | no | no | no | no | no | no | no |
Pancreatic autoantibody | negative | negative | negative | negative | negative | negative | negative | negative | negative |
Urine sugar | negative | negative | negative | negative | negative | negative | negative | negative | negative |
Other problems | EP at 2y | ||||||||
Treatment and evolution | Diet, active exercise | Glibenclamide 0.3 mg/kg/d, stopped at 1y4m | Diet | Diet, active exercise | Diet, active exercise | Diet, active Exercise | Diet, active exercise | Diet, active Exercise | Diet, active exercise |
Recent Follow-up | |||||||||
Duration of follow-up | 5 y | 2 y 4 m | 2 y1m | 2 y6 m | 1 y10 m | 2 y | 1 y1 m | 9 m | 4 y |
Age | 5 y1 m | 2 y7m | 2 y2 m | 9 y5 m | 10 y11 m | 4 y9 m | 5 y9 m | 9y8 m | 12 y6 m |
BMI percentile | 50th | 25th | 50th | 50th | 25th | 25th | 85th | 50th | 50th |
HbA1c (%/mmol/mol) | 6.0/42.1 | 6.4/46.4 | 6.1/43.2 | 5.8/39.9 | 5.9/41.0 | 6.0/42.1 | 6.4/46.4 | 6.5/47.5 | 7.5/58.4 |
FPG (mmol/L) | 7.6 | 6.5 | 6.5 | 6.1 | 6.4 | 6.9 | 7.5 | 6.7 | 8.0 |
Fasting Ins (pmol/L) | 13.9 | 10.4 | 0.99 | 8.6 | 14.9 | 16.6 | 5.9 | 9.2 | 6.7 |
OGTT 2hPG (mmol/L) | 8.7 | 6.7 | 8.0 | 7.4 | 9.9 | 8.7 | 8.9 | 8.8 | 12.6 |
2hPG increment (mmol/L) | 1.1 | 0.2 | 1.5 | 1.3 | 3.5 | 1.8 | 1.4 | 2.1 | 4.6 |
OGTT 2 h Ins (pmol/L) | 90.6 | 19.4 | 23.8 | 43.9 | 61.4 | 47.9 | 32.9 | 49.6 | 52.1 |
Combined with other problems | Developmental delay | EP and MR, treated with levetiracetam |